Fresenius Medical Care AG (Fresenius Medical Care AG) Interest Expense

: $-458 Mil (TTM As of Dec. 2023)

View and export this data going back to 1996. Start your Free Trial

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Fresenius Medical Care AG's interest expense for the three months ended in Dec. 2023 was $ -122 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-458 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Fresenius Medical Care AG's Operating Income for the three months ended in Dec. 2023 was $ 691 Mil. Fresenius Medical Care AG's Interest Expense for the three months ended in Dec. 2023 was $ -122 Mil. Fresenius Medical Care AG's Interest Coverage for the quarter that ended in Dec. 2023 was 5.68. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Fresenius Medical Care AG Interest Expense Historical Data

The historical data trend for Fresenius Medical Care AG's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fresenius Medical Care AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

-545.62

-498.76

-399.55

-381.50

-463.08

Fresenius Medical Care AG Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense																-106.01	-101.34	-113.41	-121.51	-121.55

Fresenius Medical Care AG Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-458 Mil.

Fresenius Medical Care AG (NYSE:FMS) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Fresenius Medical Care AG's Interest Expense for the three months ended in Dec. 2023 was $-122 Mil. Its Operating Income for the three months ended in Dec. 2023 was $691 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $11,438 Mil.

Fresenius Medical Care AG's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Dec. 2023 )	/	Interest Expense (Q: Dec. 2023 )
	=	-1	*	690.59	/	-121.545
	=	5.68

The higher the ratio, the stronger the company's financial strength is.

Fresenius Medical Care AG (Fresenius Medical Care AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Fresenius Medical Care AG (NYSE:FMS) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

FMCQF:USA FME:Italy FMEd:UK 0H9X:UK FME:Germany FMEA:Germany FME:Germany FME:Germany FMEA:Germany FME:Germany FMSC34:Brazil FME:Austria

Address

Else-Kroener-Strasse 1, Bad Homburg, HE, DEU, 61352

Website

https://www.freseniusmedicalcare.com

Fresenius Medical Care is the largest dialysis company in the world, treating about 345,000 patients from over 4,100 clinics across the globe as of December 2022. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market and benefits from being the world's only fully integrated dialysis business. Services account for roughly 80% of firmwide revenue, including care coordination and ancillary operations, while products account for the other roughly 20%. Products typically enjoy a higher margin, making them a strong contributor to the bottom line.

Executives

Helen Pring Giza

Board of Directors